Latest From MacroGenics Inc.
MacroGenics' BLA for full approval in the US is under way and the company already has established a manufacturing facility in preparation for a launch.
Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.
MeiraGTx was the first to go public in the US in June after six drug developer IPOs launched in May. With returns for this year's first-time biopharma offerings more than doubling from 9% at the end of April to 23.6% as of June 8, four new companies have filed and six have set terms for future IPOs.
Denali Therapeutics will pay around $470m in upfront and milestone payments to acquire its CNS bispecific antibody development partner F-star Gamma, lending credence to F-star’s business model of individual, asset-specific spin offs.
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- MacroGenics Inc.
- Senior Management
Scott Koenig, MD, PhD, Pres. & CEO
James Karrels, SVP, CFO
Ezio Bonvini, MD, SVP, Research & CSO
Eric Risser, VP, Bus. Dev. & Portfolio Mgmt. & CBO
Jon Wigginton, MD, SVP, Clin. Dev. & CMO
- Contact Info
Phone: (301) 251-5172
9704 Medical Center Dr.
Rockville, MD 20850
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.